Hi Willius, The fundamentals have just got better here in the...

Hi Willius, 

The fundamentals have just got better here in the small time I’ve been invested.  

The palatability issues you have commented on, it was an issue, addressed.  The multiple announcements regarding bioavailability, active metabolites that are not causing toxicity & clinically significant side effects, but adding to the evidence of efficacy & ease of treatment & less cost for owners by $thousands of dollars.   We are now in a Phase 1 (as of tomorrow, my apologies, due to the dateline & being done in the USA) for healthy canines in preparation for Ph2.  PAA have already worked out if food plays a role in drug absorption & tolerability.  It’s really coming along nicely for Ph2 trials.  This is the last step.  The existing Elanco data will really help us, but of course a different indication & dose dependent. This is what is happening now.  Dotting the I’s & crossing the T’s PRIOR to clinical trials & ensuring we have enough in the bank to complete them.